Traders should treat this as routine and non-informative. The sales represent a tiny fraction of each executive's holdings and are paired with option exercises, suggesting tax- or diversification-driven dispositions. No bearish signal from this cluster. Monitor next quarterly filing for any shift in business momentum, but this insider activity alone does not warrant action.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 27 $567.74entry
- T+1 · 6mo ago −1.06%α −1.62% · $561.70
- T+5 · 6mo ago −3.34%α −3.81% · $548.80
- T+20 · 5mo ago −3.14%α −0.85% · $549.90
- T+60 · 3mo ago −8.67%α −10.29% · $518.50
Price Chart
How similar events traded
Executive Summary
Three top insiders at United Therapeutics (CEO, CFO, General Counsel) sold a combined ~$110K in open-market transactions over two days. The dollar amount is trivial relative to the company's $24.1B market cap (~0.0005%) and is consistent with routine stock-for-tax settlements after option exercises. The cluster pattern is weak, these are small, liquidity-driven sales, not a coordinated signal of deteriorating fundamentals.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold 47 shares for $26K on May 22 (open-market).
- CFO James Edgemond sold 40 shares for $22K on May 21 (open-market).
- General Counsel Paul Mahon sold 110 shares for $61K on May 21 (open-market).
- All three also exercised non-cash stock options or derivative conversions in the same window.
- Total open-market sales = ~$110K, or 0.0005% of the $24.1B market cap.
- No insider open-market purchases were reported in the cluster.
Financial Impact
Approximately $110,000 in insider sales, immaterial relative to $24.1B market cap.
Risk Factors
- Insider sales are small and likely liquidity-driven, but any unexpected acceleration in selling volume or pattern change in future filings would warrant closer scrutiny.
- The company has no current known catalysts or disclosures that would explain insider selling, absence of red flags is not a guarantee of continued stock performance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1779828428370 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers